First-in-human clinical trial of CAR T cell therapy with new binding mechanism shows promising early responses

Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response (CR) rate at the higher dose levels studied in the trial.

from Latest Science News -- ScienceDaily https://ift.tt/m0C1or8

Comments

Popular posts from this blog

Seismic study reveals key reason why Patagonia is rising as glaciers melt

New method to detect and visualize sperm cells recovered from forensic evidence